Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Completed · Phase 1/Phase 2
Conditions studied: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Sorafenib and everolimus may stop the growth of cancer cells by blocking blood flow to the cancer and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of sorafenib and everolimus and to see how well they work in treating patients with relapsed or refractory non-Hodgkin's lymphoma, Hodgkin's lymphoma, or multiple myeloma.
Key facts
- Study ID
- NCT00474929
- Run by
- Mayo Clinic
- People needed
- 103
- Starts
- 2007-08-29
- Expected to finish
- 2019-08-08
- Last updated by the study team
- 2019-08-20
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Holden Comprehensive Cancer Center at University of Iowa — Iowa City, Iowa, United States
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.